Meeting
2016 ASCO Annual Meeting
Development of novel backbones for the treatment of peripheral T-cell lymphoma (PTCL): The pralatrexate/ romidepsin doublet.
Authors
Jennifer Effie Amengual
Columbia University Medical Center, New York, NY
Jennifer Effie Amengual , Renee Lichtenstein , Celeste Rojas , Ahmed Sawas , Changchun Deng , Donald Steven Colbourn , Emily Lichtenstein , Karen Khan , Michael J. Smith , Heather Dials , Owen A. O'Connor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Other Novel Agents
Clinical Trial Registration Number
NCT01947140
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2552)
DOI
10.1200/JCO.2016.34.15_suppl.2552
Abstract #
2552
Poster Bd #
252
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma.
First Author: Niloufer Khan
Poster
2013 ASCO Annual Meeting
ROCHOP study: A phase III randomized study of CHOP compared to romidepsin-CHOP in untreated peripheral T-cell lymphoma.
First Author: Richard Delarue
Poster
2013 ASCO Annual Meeting
Phase II study of chidamide (CS055), a new subtype-selective oral histone deacetylase inhibitor, in patients with relapsed or refractory peripheral T-cell lymphoma.
First Author: Yuan-Kai Shi
Poster
2024 ASCO Annual Meeting
HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory diffuse large B-cell lymphoma: A single agent phase IIa trial.
First Author: Lijuan Chen